Skip to main content


Precision Oncology

​​​​​​​Precision OncologyDue to the heterogeneous nature of tumors, molecular profiling is crucial to our understanding of how genomics plays a role in the cause or development of an individual cancer. Such tumor profiles can subsequently be applied to exclusively tailor cancer therapies to directly target a causative mutation for a malignancy, ultimately achieving a personalized and precise approach to cancer treatment. This approach is termed precision oncology.

Precision oncology has made progress in leaps and bounds in recent years and is currently at the heart of revolutionizing cancer research. As this research continues to develop and evolve, the enhanced use of precision oncology in cancer treatment ultimately aims to improve prognosis and outcomes for patients.

We are therefore very proud to announce a new cross-journal thematic series focusing on precision oncology. This cross-journal thematic series of original research and review articles aims to gather the latest research on precision oncology. It will focus on how precision oncology has shaped advances in the impact of non-coding RNAs in epigenetics and cancer, immunotherapy and tumor biology, and the clinical significance of various therapies in a range of cancers. We are seeking research that applies precision oncology in clinical settings; this can include, but is not limited to, cost-effectiveness studies, guidelines and educational strategies to translate information from the lab to bedside, and vice versa.

We encourage researchers to visit the websites listed below of each individual journal within this collection, for information on criteria and suitability of their manuscript before deciding where to submit. When submitting your manuscript, please note in your cover letter that you are submitting to the 'Precision Oncology' series.

Participating journals

  • For more information about each participating journal, click on the journal name to be directed to the journal homepage or see the descriptions below.

    *If you would like to submit to BMC Medicine, we encourage sending a pre-submission enquiry to the journal for advice on whether your research will fit the journal’s scope, threshold and high clinical impact criteria. Please send an abstract of your manuscript to with a cover letter stating that you are considering submitting to the series.

  • Applied Cancer ResearchApplied Cancer Research is a multi-disciplinary journal focused on clinical, surgical, and translational research in oncology. The journal aims to be a forum for researchers, health care practitioners, and health policy makers.

    • Official journal of A.C.Camargo Cancer Center
    • Article-processing charge for each article is covered by the society
  • BMC CancerBMC Cancer considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.

    • Broad scope: from basic to translational, clinical and epidemiological research
    • Rapid publication upon acceptance
  • BMC Medicine

    BMC Medicine* publishes outstanding and influential research in all areas of clinical practice, translational medicine, medical and health advances, public health and general topics of interest to the biomedical and sociomedical professional communities.

    •  Flagship medical journal of the BMC series
    • Open access and open peer-reviewed general medical journal.

      *If you would like to submit to BMC Medicine, we encourage sending a pre-submission enquiry to the journal for advice on whether your research will fit the journal’s scope, threshold and high clinical impact criteria. Please send an abstract of your manuscript to with a cover letter stating that you are considering submitting to the series. 
  • Cancer Cell InternationalCancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques.

    • Inclusive sound science policy
    • Indexed in Science Citation Index Expanded, PubMed, Scopus, and others
  • New Content Item (1)Cancer Communications, formerly entitled Chinese Journal of Cancer, publishes basic, clinical, and translational cancer research. It welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics. 

    • Ranked in the 2nd quartile in the Oncology category of Journal Citation Reports
    • Waivers of publication costs offered for selected high quality articles
  • Cancer Convergence coverCancer Convergence connects researchers from the physical and mathematical sciences and engineering, who bring quantitative approaches, new questions, and testable hypotheses to the study of cancer, with cancer biologists and research oncologists who represent a long tradition of progress toward understanding the emergence and pathogenesis of the disease.

    • Highly renowned and distinguished Editorial Board
    • Features techniques and synergistic perspectives from different disciplines to facilitate the study and development of strategies for curing cancer
  • Cancer ImagingCancer Imaging is dedicated to publishing articles on the rapidly advancing area of imaging techniques in cancer and encompasses CT, MR, PET, ultrasound, radionuclide and multimodal imaging in all kinds of malignant tumours, plus new developments, techniques and innovations.

    • The official journal of the International Cancer Imaging Society (ICIS)
    • Ranked in the 2nd quartile in the Radiology, Nuclear Medicine & Medical Imaging category of Journal Citation Reports
  • New Content ItemCancer is a group of diseases driven by inherently nanostructural problems. As such, there are obvious benefits to treatments employing nanoscale structures and processes. Cancer Nanotechnology provides a forum to unite researchers working in the disciplines of both cancer research and nanotechnology.

    • Innovative approach to cancer research, covering all aspects from basics to clinical applications
    • Highly renowned and distinguished Editorial Board
  • Cancers of the Head & NeckEncompassing all stages from aetiology to survivorship, Cancers of the Head & Neck is dedicated to publishing the latest pre-clinical and translational research in the field, exploring all aspects of head and neck cancers.

    • Distinguished international Editorial Board
    • Publishes the latest pre-clinical and translational research of head and neck cancers
  • New Content Item (1)Diagnostic Pathology covers all aspects of surgical pathology, including classic diagnostic pathology, prognosis-related diagnosis and therapy-related findings.

    • Accepted articles are published within 16 days
    • Color figures are free to publish
  • Infectious Agents and CancerInfectious Agents and Cancer publishes novel insights on the associations between chronic infections and cancer. The journal focuses on basic, clinical, epidemiological and translational research and has a particular interest in the innovative field of molecular research in cancer causation.

    • Affiliated with the African Organisation for Research & Training In Cancer (AORTIC)
    • Publishing insights on the association between chronic infections and cancer
  • Radiation OncologyRadiation Oncology publishes interdisciplinary research related to the treatment of cancer using radiation. The journal brings together the latest research, advances and innovations in the field with a strong focus on molecular and cellular radiation biology, radiation physics, radiation technology and clinical oncology.

    • Ranked in the 2nd quartile in the Radiology, Nuclear Medicine & Medical Imaging category of Journal Citation Reports
    • An experienced Editorial Board composed of researchers and clinicians currently working in the field
  1. Content type: Research article

    Multiple primary melanomas (MPM) occur up to 8% of patients with cutaneous malignant melanoma (CMM). They are often sporadic harbouring several somatic mutations, but also familial cases harbouring a CDKN2A germl...

    Authors: Milena Casula, Panagiotis Paliogiannis, Fabrizio Ayala, Vincenzo De Giorgi, Ignazio Stanganelli, Mario Mandalà, Maria Colombino, Antonella Manca, Maria Cristina Sini, Corrado Caracò, Paolo Antonio Ascierto, Rosanna Rita Satta, Amelia Lissia, Antonio Cossu and Giuseppe Palmieri

    Citation: BMC Cancer 2019 19:772

    Published on:

  2. Content type: Case report

    ROS1 rearrangements are validated drivers in lung cancer, which have been identified in a small subset (1–2%) of patients with non-small cell lung cancer (NSCLC). To date, 18 fusion genes of ROS1 have been identi...

    Authors: Shuguang Xu, Wenxian Wang, Chunwei Xu, Xingliang Li, Junhui Ye, Youcai Zhu and Ting Ge

    Citation: BMC Cancer 2019 19:769

    Published on:

  3. Content type: Research article

    Salivary adenoid cystic carcinoma (SACC) can recur after removal of the primary tumor and treatment, where they can keep no clinical symptoms and dormant state for 10–15 years. NR2F1 has been demonstrated to r...

    Authors: Xiao-lei Gao, Min Zheng, Hao-fan Wang, Lu-ling Dai, Xiang-hua Yu, Xiao Yang, Xin Pang, Li Li, Mei Zhang, Sha-sha Wang, Jing-biao Wu, Ya-Jie Tang, Xin-hua Liang and Ya-ling Tang

    Citation: BMC Cancer 2019 19:743

    Published on:

  4. Content type: Primary research

    MicroRNAs (miRNAs) play a pivotal role in hepatocellular carcinoma (HCC) progression and have been confirmed to participate in the carcinogenesis and development of HCC. However, the relationship between miR-4...

    Authors: Yixi Zhang, Zebin Zhu, Shanzhou Huang, Qiang Zhao, Changjun Huang, Yunhua Tang, Chengjun Sun, Zhiheng Zhang, Linhe Wang, Huadi Chen, Maogen Chen, Weiqiang Ju and Xiaoshun He

    Citation: Cancer Cell International 2019 19:198

    Published on:

  5. Content type: Research article

    Detection of somatic mutations is a mandatory practice for therapeutic definition in precision oncology. However, somatic mutation detection protocols use DNA from formalin-fixed and paraffin-embedded (FFPE) t...

    Authors: C. M. Berra, G. T. Torrezan, C. A. de Paula, R. Hsieh, S. V. Lourenço and D. M. Carraro

    Citation: Applied Cancer Research 2019 39:7

    Published on:

  6. Content type: Review

    Colorectal cancer (CRC) is one type of tumor with the highest frequency and mortality worldwide. Although current treatments increase patient survival, it is important to detect CRC in early stages; however, m...

    Authors: Elsa N. Garza Treviño, Paulina Delgado González, Carlos I. Valencia Salgado and Alejandra Martinez Garza

    Citation: Cancer Cell International 2019 19:173

    Published on:

  7. Content type: Primary research

    Triple negative breast cancer (TNBC) is a specific subtype of breast cancer with a poor prognosis due to its aggressive biological behaviour and lack of therapeutic targets. We aimed to explore some novel gene...

    Authors: Xuemei Lv, Miao He, Yanyun Zhao, Liwen Zhang, Wenjing Zhu, Longyang Jiang, Yuanyuan Yan, Yue Fan, Hongliang Zhao, Shuqi Zhou, Heyao Ma, Yezhi Sun, Xiang Li, Hong Xu and Minjie Wei

    Citation: Cancer Cell International 2019 19:172

    Published on:

  8. Content type: Research article

    A major barrier to effective treatment of glioblastoma (GBM) is the large intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials, patient heterogeneity in response to ther...

    Authors: Erlend Skaga, Evgeny Kulesskiy, Artem Fayzullin, Cecilie J. Sandberg, Swapnil Potdar, Aija Kyttälä, Iver A. Langmoen, Aki Laakso, Emília Gaál-Paavola, Markus Perola, Krister Wennerberg and Einar O. Vik-Mo

    Citation: BMC Cancer 2019 19:628

    Published on:

  9. Content type: Research article

    Cancer patients with advanced disease routinely exhaust available clinical regimens and lack actionable genomic medicine results, leaving a large patient population without effective treatments options when th...

    Authors: Noah E. Berlow, Rishi Rikhi, Mathew Geltzeiler, Jinu Abraham, Matthew N. Svalina, Lara E. Davis, Erin Wise, Maria Mancini, Jonathan Noujaim, Atiya Mansoor, Michael J. Quist, Kevin L. Matlock, Martin W. Goros, Brian S. Hernandez, Yee C. Doung, Khin Thway…

    Citation: BMC Cancer 2019 19:593

    Published on:

  10. Content type: Study protocol

    Detection of circulating tumor DNA (ctDNA) is a promising method for postoperative surveillance of lung cancer. However, relatively low positive rate in early stage patients restricts its application. Aberrant...

    Authors: Guannan Kang, Kezhong Chen, Fan Yang, Shannon Chuai, Heng Zhao, Kai Zhang, Bingsi Li, Zhihong Zhang and Jun Wang

    Citation: BMC Cancer 2019 19:579

    Published on:

  11. Content type: Primary research

    Pyruvate kinase isozyme type M2 (PKM2) catalyzes the final step in glycolysis and has been found to be up-regulated in multiple human malignancies. However, whether PKM2 regulates the radiosensitivity of human...

    Authors: Yanzhu Lin, Hui Zhai, Yi Ouyang, Zhiyuan Lu, Chengbiao Chu, Qianting He and Xinping Cao

    Citation: Cancer Cell International 2019 19:129

    Published on:

  12. Content type: Research article

    Lung adenocarcinoma is the most common type of lung cancers. Whole-genome sequencing studies disclosed the genomic landscape of lung adenocarcinomas. however, it remains unclear if the genetic alternations cou...

    Authors: Jiaxian Yu, Yueming Hu, Yafei Xu, Jue Wang, Jiajie Kuang, Wei Zhang, Jianlin Shao, Dianjing Guo and Yejun Wang

    Citation: BMC Cancer 2019 19:263

    Published on:

  13. Content type: Primary research

    The abnormal expression of many long non-coding RNAs (lncRNAs) has been reported in the progression of various tumors. However, the potential biological roles and regulatory mechanisms of long non-coding RNAs ...

    Authors: Qingmei Wang, Rongzhang He, Tan Tan, Jia Li, Zheng Hu, Weihao Luo, Lili Duan, Wenna Luo and Dixian Luo

    Citation: Cancer Cell International 2019 19:40

    Published on:

  14. Content type: Research article

    Breast cancer patients who have not previously attended mammography screening may be more likely to discontinue adjuvant hormone therapy and therefore have a worse disease prognosis.

    Authors: Wei He, Louise Eriksson, Sven Törnberg, Fredrik Strand, Per Hall and Kamila Czene

    Citation: BMC Medicine 2019 17:24

    Published on:

  15. Content type: Primary research

    Circulating tumor cells (CTCs) have been described as a population of cells that may seed metastasis, which is a reliable target for the prevention of metastases in lung cancer patients at the early stage. The...

    Authors: Zujun Que, Bin Luo, Zhiyi Zhou, Changsheng Dong, Yi Jiang, Lin Wang, Qihui Shi and Jianhui Tian

    Citation: Cancer Cell International 2019 19:21

    Published on:

  16. Content type: Primary research

    Although low-grade serous ovarian cancer (LGSC) is rare, case-fatality rates are high as most patients present with advanced disease and current cytotoxic therapies are not overly effective. Recognizing that t...

    Authors: Marta Llaurado Fernandez, Amy Dawson, Joshua Hoenisch, Hannah Kim, Sylvia Bamford, Clara Salamanca, Gabriel DiMattia, Trevor Shepherd, Mattia Cremona, Bryan Hennessy, Shawn Anderson, Stanislav Volik, Colin C. Collins, David G. Huntsman and Mark S. Carey

    Citation: Cancer Cell International 2019 19:10

    Published on:

  17. Content type: Research article

    Chronic diseases such as chagasic megaesophagus (secondary to Chagas’ disease) have been suggested as etiological factors for esophageal squamous cell carcinoma; however, the molecular mechanisms involved are ...

    Authors: Fernanda Franco Munari, Adriana Cruvinel-Carloni, Croider Franco Lacerda, Antônio Talvane Torres de Oliveira, Cristovam Scapulatempo-Neto, Sandra Regina Morini da Silva, Eduardo Crema, Sheila Jorge Adad, Maria Aparecida Marchesan Rodrigues, Maria Aparecida Coelho Arruda Henry, Denise Peixoto Guimarães, Adhemar Longatto-Filho and Rui Manuel Reis

    Citation: Infectious Agents and Cancer 2018 13:43

    Published on:

  18. Content type: Primary research

    Helicobacter pylori (H. pylori)-induced gastric cancer is an intricate progression of immune response against H. pylori infection. IL-16, TGF-β1 and TLR4 pathways were the mediators involved in the immune respons...

    Authors: Bangshun He, Tao Xu, Bei Pan, Yuqin Pan, Xuhong Wang, Jingwu Dong, Huiling Sun, Xueni Xu, Xiangxiang Liu and Shukui Wang

    Citation: Cancer Cell International 2018 18:191

    Published on: